Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin ® ) in patients with advanced non-squamous non-small cell lung cancer
ConclusionsThe population PK of PF-06439535 and bevacizumab-EU were well characterized by a two-compartment model. Covariate analysis did not reveal any appreciable differences between PK parameters for PF-06439535 and bevacizumab-EU in patients with NSCLC.Clinical trial registrationClinicalTrials.gov, NCT02364999.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Drugs & Pharmacology | Lung Cancer | Non-Small Cell Lung Cancer | Study